Here is how HCA Healthcare (HCA) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.
Vous n'êtes pas connecté
Expanding aging population and the increasing demand for affordable health products are likely to have boosted the performance of healthcare stocks in Q2. CI, UHS, HCA & THC are potential outperformers.
Here is how HCA Healthcare (HCA) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.
RBRK's fiscal second-quarter performance is likely to reflect benefits from its expanding clientele and increased demand for its data security...
The US Presidential Election 2024 brings two distinct healthcare visions from Kamala Harris and Donald Trump, reflecting broader ideological...
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks....
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks....
Samsara's fiscal second-quarter performance benefits from expanding its customer base.
Samsara's fiscal second-quarter performance benefits from expanding its customer base.
DSGX's Q2 fiscal 2025 performance is likely to have gained from robust demand for its differentiated offerings and buyout strategies.
HIMS is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt...
IOT's second-quarter fiscal 2025 performance is likely to reflect benefits from its diversified portfolio and expanding customer base.